JP2019510052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510052A5 JP2019510052A5 JP2018551147A JP2018551147A JP2019510052A5 JP 2019510052 A5 JP2019510052 A5 JP 2019510052A5 JP 2018551147 A JP2018551147 A JP 2018551147A JP 2018551147 A JP2018551147 A JP 2018551147A JP 2019510052 A5 JP2019510052 A5 JP 2019510052A5
- Authority
- JP
- Japan
- Prior art keywords
- strain
- composition
- vibrio
- icp
- strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 57
- 241001515965 unidentified phage Species 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 230000002101 lytic effect Effects 0.000 claims description 29
- 241000607598 Vibrio Species 0.000 claims description 26
- 101001044255 Entamoeba histolytica Amoebiasin-2 Proteins 0.000 claims description 20
- 206010008631 Cholera Diseases 0.000 claims description 18
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 231100000331 toxic Toxicity 0.000 claims description 13
- 230000002588 toxic effect Effects 0.000 claims description 13
- 101001042083 Entamoeba histolytica Amoebiasin-1 Proteins 0.000 claims description 12
- 241000607626 Vibrio cholerae Species 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- 210000002845 virion Anatomy 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 8
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 238000010171 animal model Methods 0.000 claims description 4
- 229940118696 vibrio cholerae Drugs 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 230000002934 lysing effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 241000607337 Aliivibrio logei Species 0.000 claims 2
- 241000122170 Aliivibrio salmonicida Species 0.000 claims 2
- 241001600138 Aliivibrio wodanis Species 0.000 claims 2
- 241001453243 Campylobacter sputorum subsp. bubulus Species 0.000 claims 2
- 241000305093 Enterovibrio calviensis Species 0.000 claims 2
- 241000303324 Glaciibacter superstes Species 0.000 claims 2
- 241000466024 Isotomurus gallicus Species 0.000 claims 2
- 241000736255 Istiompax indica Species 0.000 claims 2
- 241000279652 Ixora casei Species 0.000 claims 2
- 241000287530 Psittaciformes Species 0.000 claims 2
- 241000332146 Vibrio aerogenes Species 0.000 claims 2
- 241001135143 Vibrio aestuarianus Species 0.000 claims 2
- 241001656470 Vibrio agarivorans Species 0.000 claims 2
- 241001231453 Vibrio albensis Species 0.000 claims 2
- 241001500064 Vibrio areninigrae Species 0.000 claims 2
- 241000452627 Vibrio artabrorum Species 0.000 claims 2
- 241001672646 Vibrio atlanticus Species 0.000 claims 2
- 241000549284 Vibrio atypicus Species 0.000 claims 2
- 241000674191 Vibrio azureus Species 0.000 claims 2
- 241000681719 Vibrio brasiliensis Species 0.000 claims 2
- 241000607323 Vibrio campbellii Species 0.000 claims 2
- 241000690888 Vibrio chagasii Species 0.000 claims 2
- 241000607296 Vibrio cincinnatiensis Species 0.000 claims 2
- 241001407018 Vibrio coralliilyticus Species 0.000 claims 2
- 241001025870 Vibrio crassostreae Species 0.000 claims 2
- 241000219284 Vibrio cyclitrophicus Species 0.000 claims 2
- 241000607306 Vibrio diazotrophicus Species 0.000 claims 2
- 241001349548 Vibrio ezurae Species 0.000 claims 2
- 241000607291 Vibrio fluvialis Species 0.000 claims 2
- 241001552433 Vibrio fortis Species 0.000 claims 2
- 241001148070 Vibrio furnissii Species 0.000 claims 2
- 241000607339 Vibrio gazogenes Species 0.000 claims 2
- 241001180047 Vibrio gigantis Species 0.000 claims 2
- 241000607618 Vibrio harveyi Species 0.000 claims 2
- 241000694781 Vibrio hepatarius Species 0.000 claims 2
- 241000210080 Vibrio hippocampi Species 0.000 claims 2
- 241000276415 Vibrio hispanicus Species 0.000 claims 2
- 241001268204 Vibrio ichthyoenteri Species 0.000 claims 2
- 241000690894 Vibrio kanaloae Species 0.000 claims 2
- 241000965623 Vibrio lentus Species 0.000 claims 2
- 241000369309 Vibrio litoralis Species 0.000 claims 2
- 241000607334 Vibrio mediterranei Species 0.000 claims 2
- 241001135144 Vibrio metschnikovii Species 0.000 claims 2
- 241000501793 Vibrio mytili Species 0.000 claims 2
- 241000607365 Vibrio natriegens Species 0.000 claims 2
- 241001148073 Vibrio navarrensis Species 0.000 claims 2
- 241000681718 Vibrio neptunius Species 0.000 claims 2
- 241000607359 Vibrio nereis Species 0.000 claims 2
- 241001135145 Vibrio nigripulchritudo Species 0.000 claims 2
- 241001135140 Vibrio orientalis Species 0.000 claims 2
- 241000690895 Vibrio pacinii Species 0.000 claims 2
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims 2
- 241000896074 Vibrio pectenicida Species 0.000 claims 2
- 241001490532 Vibrio penaeicida Species 0.000 claims 2
- 241000092104 Vibrio ponticus Species 0.000 claims 2
- 241000607269 Vibrio proteolyticus Species 0.000 claims 2
- 241001407024 Vibrio rotiferianus Species 0.000 claims 2
- 241001086881 Vibrio ruber Species 0.000 claims 2
- 241000193098 Vibrio scophthalmi Species 0.000 claims 2
- 241001148079 Vibrio splendidus Species 0.000 claims 2
- 241000510690 Vibrio tapetis Species 0.000 claims 2
- 241001148039 Vibrio tubiashii Species 0.000 claims 2
- 241000607265 Vibrio vulnificus Species 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 claims 1
- 241001520316 Phascolarctidae Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000607284 Vibrio sp. Species 0.000 claims 1
- 230000001857 anti-mycotic effect Effects 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 239000002543 antimycotic Substances 0.000 claims 1
- -1 antiprotozoals Substances 0.000 claims 1
- 229940036589 antiprotozoals Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 238000009155 rehydration therapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000001320 lysogenic effect Effects 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 101150055431 ompU gene Proteins 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 201000009881 secretory diarrhea Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 101150021331 toxR gene Proteins 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- NGZXDRGWBULKFA-NSOVKSMOSA-N (+)-Bebeerine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-NSOVKSMOSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101100284517 Aneurinibacillus thermoaerophilus hddC gene Proteins 0.000 description 1
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000348 Angiotensin-3 Human genes 0.000 description 1
- 101800000738 Angiotensin-3 Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101710105759 Major outer membrane porin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 101000773513 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) Uncharacterized protein MK0525 Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000268342 Viscaria vulgaris Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 101150039741 hldD gene Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316704P | 2016-04-01 | 2016-04-01 | |
| US62/316,704 | 2016-04-01 | ||
| PCT/US2017/025305 WO2017173229A1 (en) | 2016-04-01 | 2017-03-31 | Methods and compositions for preventing infection by a vibrio species |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510052A JP2019510052A (ja) | 2019-04-11 |
| JP2019510052A5 true JP2019510052A5 (enExample) | 2019-05-30 |
Family
ID=59966476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551147A Pending JP2019510052A (ja) | 2016-04-01 | 2017-03-31 | Ｖｉｂｒｉｏ種による感染を防止するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10953053B2 (enExample) |
| EP (1) | EP3436611A4 (enExample) |
| JP (1) | JP2019510052A (enExample) |
| KR (4) | KR20240005101A (enExample) |
| CN (1) | CN109310722A (enExample) |
| CA (1) | CA3026327A1 (enExample) |
| WO (1) | WO2017173229A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2463181B (en) | 2007-05-14 | 2013-03-27 | Univ New York State Res Found | Induction of a physiological dispersion response in bacterial cells in a biofilm |
| CN107904211B (zh) * | 2017-10-13 | 2024-03-19 | 深圳先进技术研究院 | 副溶血弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904214A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107805629B (zh) * | 2017-10-13 | 2023-03-21 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904212A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107805630B (zh) * | 2017-10-13 | 2024-03-19 | 深圳先进技术研究院 | 副溶血弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN107904213A (zh) * | 2017-10-13 | 2018-04-13 | 深圳先进技术研究院 | 溶藻弧菌噬菌体及包含该噬菌体的杀菌组合物 |
| CN108048412A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-4及包含该噬菌体的杀菌组合物及其应用 |
| CN107988172A (zh) * | 2017-11-20 | 2018-05-04 | 深圳先进技术研究院 | 裂性弧菌噬菌体VpaJT-1及包含该噬菌体的杀菌组合物及其应用 |
| CN107988171A (zh) * | 2017-11-20 | 2018-05-04 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValSw4-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108048411A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-2及包含该噬菌体的杀菌组合物及其应用 |
| CN108048410B (zh) * | 2017-11-20 | 2023-06-27 | 深圳先进技术研究院 | 裂性弧菌噬菌体VspSw-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108070570A (zh) * | 2017-11-20 | 2018-05-25 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValDsh-1及包含该噬菌体的杀菌组合物及其应用 |
| CN108048409A (zh) * | 2017-11-20 | 2018-05-18 | 深圳先进技术研究院 | 裂性弧菌噬菌体ValLY-3及包含该噬菌体的杀菌组合物及其应用 |
| CN112236517A (zh) * | 2018-05-22 | 2021-01-15 | 学校法人自治医科大学 | 抗菌噬菌体、治疗用组合物、杀菌剂、食品、细菌鉴别试剂盒、治疗用组合物制造方法、细菌去除方法、细菌鉴别方法及动物治疗方法 |
| CN109517804B (zh) * | 2018-11-19 | 2022-06-14 | 扬州大学 | 一种具有跨种裂解特性的拟态弧菌噬菌体oy-1、制备方法及其应用 |
| CN110352880B (zh) * | 2019-08-13 | 2021-04-20 | 宁波大学 | 一种紫菜黄斑病的治疗方法 |
| CN112391358B (zh) * | 2019-08-14 | 2023-12-01 | 宁波大学 | 地中海弧菌烈性噬菌体vB_VmeM-Yong及其应用 |
| CN111826309A (zh) * | 2020-06-30 | 2020-10-27 | 武汉合缘绿色生物股份有限公司 | 一种液体生物营养菌剂及其制备方法 |
| CN112029733B (zh) * | 2020-09-24 | 2021-11-26 | 瑞科盟(青岛)生物工程有限公司 | 一株高裂解性溶藻弧菌噬菌体rdp-vp-19001及其应用 |
| CN112011520B (zh) * | 2020-10-30 | 2021-01-19 | 中国科学院南海海洋研究所 | 一种调控珊瑚菌群的温和噬菌体VneM1及其应用 |
| CN112553171B (zh) * | 2020-12-27 | 2022-06-21 | 威海长青海洋科技股份有限公司 | 一种弧菌噬菌体制剂及其应用 |
| CN112646786A (zh) * | 2021-01-21 | 2021-04-13 | 海南海壹水产种苗有限公司 | 一株坎式弧菌噬菌体快速初步分离方法 |
| CN113201505B (zh) * | 2021-04-02 | 2023-12-29 | 青岛诺安百特生物技术有限公司 | 一株具备跨种裂解能力的溶藻弧菌噬菌体、其噬菌体组合物及其应用 |
| KR102774411B1 (ko) * | 2021-10-27 | 2025-02-27 | 전북대학교산학협력단 | 재증식 풀 컬쳐 기반 박테리오파지 스크리닝 방법 |
| CN116103183A (zh) * | 2022-03-30 | 2023-05-12 | 山东科技大学 | 一株脱除高盐硬水中钙离子的巨大弧菌及其应用 |
| CN114774371B (zh) * | 2022-06-21 | 2022-09-13 | 中国海洋大学 | 一种弧菌噬菌体及其应用 |
| CN115820569B (zh) * | 2022-08-09 | 2025-01-14 | 青岛诺安百特生物技术有限公司 | 一株奥氏弧菌噬菌体、其噬菌体组合物及其应用 |
| KR20240058217A (ko) | 2022-10-25 | 2024-05-03 | 주식회사 엘지에너지솔루션 | 고분자 고체 전해질 및 이의 제조방법 |
| CN120058874B (zh) * | 2025-04-29 | 2025-09-09 | 中国疾病预防控制中心传染病预防控制所 | 噬菌体蛋白Gp37及其在制备抑制霍乱弧菌定植和毒素分泌的制剂中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2186962A1 (en) | 1994-04-05 | 1995-10-12 | Richard M. Carlton | Antibacterial therapy with genotypically modified bacteriophage |
| AU4313101A (en) | 2000-01-11 | 2001-07-24 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
| US8956628B2 (en) | 2007-12-13 | 2015-02-17 | Zoetis Products Llc | Bacteriophage preparations and method of use thereof |
| CL2012002902A1 (es) * | 2012-10-17 | 2013-05-03 | Univ Chile | Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas. |
| US9839657B2 (en) * | 2012-10-30 | 2017-12-12 | Deerland Enzymes, Inc. | Prebiotic compositions comprising one or more types of bacteriophage |
| WO2015034872A2 (en) * | 2013-09-05 | 2015-03-12 | Massachusetts Institute Of Technology | Tuning microbial populations with programmable nucleases |
-
2017
- 2017-03-31 JP JP2018551147A patent/JP2019510052A/ja active Pending
- 2017-03-31 CN CN201780033655.0A patent/CN109310722A/zh active Pending
- 2017-03-31 EP EP17776749.8A patent/EP3436611A4/en not_active Withdrawn
- 2017-03-31 WO PCT/US2017/025305 patent/WO2017173229A1/en not_active Ceased
- 2017-03-31 CA CA3026327A patent/CA3026327A1/en not_active Abandoned
- 2017-03-31 KR KR1020237043358A patent/KR20240005101A/ko not_active Ceased
- 2017-03-31 KR KR1020187031275A patent/KR20190005846A/ko not_active Ceased
- 2017-03-31 KR KR1020237030274A patent/KR102755264B1/ko active Active
- 2017-03-31 KR KR1020227033895A patent/KR20220138015A/ko not_active Ceased
-
2018
- 2018-09-28 US US16/145,836 patent/US10953053B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510052A5 (enExample) | ||
| US10953053B2 (en) | Methods and compositions for preventing infection by a Vibrio species | |
| CN101970644B (zh) | 新型噬菌体和包含所述噬菌体的抗菌组合物 | |
| JP5079885B2 (ja) | 新規バクテリオファージおよびこれを含む抗菌組成物 | |
| Guang-Han et al. | Experimental phage therapy for Burkholderia pseudomallei infection | |
| JP2011514802A (ja) | 新規バクテリオファージおよびこれを含む抗菌組成物 | |
| AU2016209252B2 (en) | Novel Shigella bacteriophages and uses thereof | |
| JP5872700B2 (ja) | 新規バクテリオファージ及びそれを含む抗菌組成物 | |
| US20160076004A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| CA2541941C (en) | Anti-bacterial phage tail compositions and uses thereof | |
| US8846368B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
| Nicolas et al. | In ovo administration of a phage cocktail partially prevents colibacillosis in chicks | |
| Pyzik et al. | Experimental Phage Therapies in Companion Animals with A Historical Review | |
| EP4111865B1 (en) | Antibacterial formulation of a mixture of bacteriophages for use in preventing or treating diseases caused by salmonella spp. | |
| US8771936B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
| RU2717451C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| US20250041367A1 (en) | Bacteriophages and use thereof for the treatment or prevention of infection caused by e. coli | |
| BR112022006931B1 (pt) | Formulação antibacteriana compreendendo uma mistura de bacteriófagos; uso e método de prevenção ou tratamento de doenças causadas por salmonella spp. em animais de fazenda por administração oral da formulação | |
| Carrias | Evaluation of biological agents for controlling enteric septicemia of catfish | |
| KR20240021316A (ko) | 박테리오파지를 포함하는 살모넬라 타이피무리움 증식 억제용 조성물 | |
| Lopes | Combined Inativation of Escherichia Coli by Phages and Antibiotics | |
| Connerton et al. | Using antimicrobial cultures, bacteriocins and bacteriophages to reduce carriage of food-borne bacterial pathogens in poultry | |
| Jamalludeen | Phages against porcine post-weaning diarrhea due to O149 Escherichia coli |